How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,654 results for

Chronic Hepatitis B Carrier

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B

/treatment Phase HBV Drug: Antroquinonol Other: placebo Phase 2 Detailed Description: Hepatitis B virus infection is a worldwide disease and is still the most common cause of hepatocellular carcinoma (HCC). Those carriers in China account for 33% of all chronic carriers globally. A big epidemiological study of patients with chronic hepatitis B has revealed that baseline HBV DNA level or cirrhosis is an independent predictor for the occurrence of HCC. Antroquinonol is a new chemical entity isolated from (...) A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2018 Clinical Trials

62. Unusual Presentation of Tuberculous Thyroid Abscess in a Background of Hashimoto's Thyroiditis in a Chronic Hepatitis B Carrier Full Text available with Trip Pro

Unusual Presentation of Tuberculous Thyroid Abscess in a Background of Hashimoto's Thyroiditis in a Chronic Hepatitis B Carrier Tuberculosis of thyroid gland is a very rare disease. It has variable presentations and may be sometimes associated with autoimmune thyroiditis. We report a case of 45-year-old male, with left sided painless neck swelling, with a purulent discharging sinus over it associated with night sweats and loss of appetite. Thyroid imaging disclosed heterogeneous enhancement (...) of left lobe of thyroid gland with internal vascularity and coarse calcifications. Core needle biopsy revealed caseous necrosis and AFB positivity. Patient had thyroid peroxidase antibody and thyroglobulin antibody positivity and the rest of thyroid function tests were normal. Patient had positive Mantoux test, hepatitis B surface Ag, and low viral DNA. The patient was diagnosed as being a case of tuberculous abscess of thyroid gland and was put on antitubercular therapy for 2 months. Patient

2016 Case reports in surgery

63. Effect of Polyherbal Formulation in Chronic Inactive Carriers of Hepatitis B Virus

Effect of Polyherbal Formulation in Chronic Inactive Carriers of Hepatitis B Virus Effect of Polyherbal Formulation in Chronic Inactive Carriers of Hepatitis B Virus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Effect of Polyherbal Formulation in Chronic Inactive Carriers of Hepatitis B Virus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02899130 Recruitment Status : Recruiting First Posted : September 14, 2016

2016 Clinical Trials

64. Effectiveness and cost-effectiveness of antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility

foreign countries with high HBsAg carrier rates were shown to be two times less likely to adhere to HBsAg screening than Italian women. Supplementary efforts were suggested to improve the effectiveness of the programme among foreign-born women [27]. Another Italian study evaluated compliance with a protocol for the prevention of perinatal hepatitis B infection in public and private hospitals of 13 Italian regions between 2008 and 2009. Prevalence of HBsAg among pregnant women varied between 0.4 (...) hepatitis B screening. Screening revealed that in 87% of cases the HBV carrier status was previously unknown. The cost of screening equated GBP 1 013 per new diagnosis, which was considered to be highly cost-effective considering the morbidity and mortality associated with vertically transmitted hepatitis B. Selective screening would have missed a significant number of those infected. Opt-out screening was concluded to be more appropriate than selective screening, with the added advantage of being

2017 European Centre for Disease Prevention and Control - Literature Reviews

65. The sero-prevalence of anti-adenovirus 5 neutralizing antibodies is independent of a chronic hepatitis B carrier state in China Full Text available with Trip Pro

The sero-prevalence of anti-adenovirus 5 neutralizing antibodies is independent of a chronic hepatitis B carrier state in China We investigated the prevalence of neutralizing antibodies (NA) to human Adenovirus (Ad) 5 both in healthy subjects (HS) and Chronic Hepatitis B (CHB) patients in Shanghai. Detection of anti-Ad5 NA (percentage of detection and titers) was similar between HS and CHB patients. A high percentage of subjects harbored no detectable antibodies (32.2 %) while proportion

2015 Archives of Virology

66. Birth order and risk of hepatocellular carcinoma in chronic carriers of hepatitis B virus: a case-control study in The Gambia. (Abstract)

Birth order and risk of hepatocellular carcinoma in chronic carriers of hepatitis B virus: a case-control study in The Gambia. Early age at infection with Hepatitis B virus (HBV) increases the risk of chronic infection. Moreover, early HBV infection may further independently increase the risk of hepatocellular carcinoma (HCC) beyond its effect on chronicity.The distribution of birth order, a proxy for mode and timing of HBV transmission, was compared in The Gambia between hepatitis B surface (...) fourth birth order respectively (P = 0.01). A similar inverse association was observed in the hospital-based case-control comparison (P = 0.04).Compared to controls, HCC cases had earlier birth order, a proxy for young maternal age and maternal HBV viraemia at birth. This finding suggests that in chronic HBV carriers perinatal mother-to-infant transmission may increase HCC risk more than horizontal transmission. Providing HBV vaccine within 24 h of birth to interrupt perinatal transmission might

2015 Liver International

67. Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali. Full Text available with Trip Pro

Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali. Hepatitis B (HB) infection is common in Mali. However, there is little information on molecular and biochemical characteristics of HB carriers.A group of 1466 adult volunteers was recruited in the district of Bamako. Confirmed HB carriers were tested for HB viral load by quantitative PCR and HBV was genotyped by sequencing of HBS. Fibrosis and hepatitis activity were measured using (...) correlated with Fibrotest scores (p = 0.0006). Among 105 subjects tested, 60% had detectable levels of R249S copies (>40 copies/mL plasma).Chronic HB carriage in adults in Bamako district is well over epidemic threshold. About 1/3 of carriers have moderate to severe liver fibrosis and 60% have detectable aflatoxin-related TP53 R249S mutation. These results support introduction of anti-HB therapies to reduce the progression towards severe liver disease.

2015 BMC Infectious Diseases

68. Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infections in Obstetrician?Gynecologists

a recommendation (1). Hepatitis C Virus Although there is currently no vaccine available to prevent infection with HCV, the risk of acquiring HCV infection appears lower than the risk of acquiring HBV infection (an average of 1.8% after a percutaneous exposure to a source patient who is infected with HCV compared with 20–60% after percutaneous exposure to a source patient who is infected with HBV and is hepatitis B e antigen positive) (3). This is presumably because most individuals chronically infected (...) . [ ] [ ] Recommendations for follow-up of health-care workers after occupational exposure to hepatitis C virus. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 1997;46:603–6. [ ] [ ] Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47(RR-19):1–39. [ ] [ ] Recommendations for preventing transmission of human immunodeficiency virus and hepatitis B virus to patients

2016 American College of Obstetricians and Gynecologists

69. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Full Text available with Trip Pro

A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. This study aimed to develop a novel therapeutic vaccine based on a unique B cell epitope and investigate its therapeutic potential against chronic hepatitis B (CHB) in animal models.A series of peptides and carrier proteins were evaluated in HBV-tolerant mice to obtain an optimised therapeutic molecule. The immunogenicity, therapeutic efficacy and mechanism of the candidate were (...) in mice, rabbits and cynomolgus monkeys. Sera and purified polyclonal IgG from the immunised animals neutralised HBV infection in vitro and mediated efficient HBV/hepatitis B virus surface antigen (HBsAg) clearance in the mice. CR-T3-SEQ13-based vaccination induced long-term suppression of HBsAg and HBV DNA in HBV transgenic mice and eradicated the virus completely in hydrodynamic-based HBV carrier mice. The suppressive effects on HBsAg were strongly correlated with the anti-HBs level after

2019 Gut

70. Hexyon - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type-b conjugate vaccine (adsorbed)

. The reported incidence has been decreased between 8% such as South-east Asia, Africa including South Africa, China, the Artic Rim etc.), medium (2 to 8% such as Eastern Europe and the Middle East including Turkey, Egypt, Morocco) and low ( 20% of all infections) and early childhood (> 60% of all infections), placing those infected at increased risk for chronic disease and its sequelae. Infants who become infected with Hep B at birth have a 70% to 90% chance of becoming chronic Hep B carriers (...) . It is estimated that approximately 75% of the world’s 350 million chronic carriers of Hep B live in these hyper endemic regions, where HBsAg positivity rates may reach 35%. Worldwide, an estimated 1 million deaths annually are attributable to Hep B-associated cirrhosis and hepatocellular carcinoma. In the low endemic areas (with a general population prevalence of 2,5 kg. Informed consent had to be given by at least one parent or other legal representative. Not permitted were multiple trial participation

2013 European Medicines Agency - EPARs

71. Hexacima - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type-b conjugate vaccine (adsorbed)

Rim etc.), medium (2 to 8% such as Eastern Europe and the Middle East including Turkey, Egypt, Morocco) and low ( 20% of all infections) and early childhood (> 60% of all infections), placing those infected at increased risk for chronic disease and its sequelae. Infants who become infected with Hep B at birth have a 70% to 90% chance of becoming chronic Hep B carriers. It is estimated that approximately 75% of the world’s 350 million chronic carriers of Hep B live in these hyper endemic regions (...) Hexacima - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type-b conjugate vaccine (adsorbed) 5 March 2013 EMA/373868/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Hexacima Common name: Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type B conjugate vaccine (adsorbed) Procedure No.: EMEA/H/C/002702

2013 European Medicines Agency - EPARs

72. Natural history of chronic hepatitis B virus infection in children in Japan: a comparison of mother-to-child transmission with horizontal transmission. (Abstract)

Natural history of chronic hepatitis B virus infection in children in Japan: a comparison of mother-to-child transmission with horizontal transmission. It is necessary to evaluate the natural history of children with hepatitis B virus (HBV) infection in each country to consider their long-term management.A multi-center observational study of children with chronic HBV infection who were diagnosed at age ≤15 years was carried out in 18 hospitals in Japan.We reviewed children with HBV infection (...) with other genotypes (33 versus 45%). Hepatitis developed at any age but before 4 years of age the incidence was high in the horizontal group. At 3 years after the onset of the hepatitis, 26% of children with MTCT and 30% of those with horizontal transmission became inactive carriers. The incidences of hepatocellular carcinoma (HCC) at 30 years of age were 6% in the MTCT group and 11% in the horizontal group.Patients with childhood-onset HBV infection with MTCT and horizontal transmission developed

2017 Journal of gastroenterology

73. Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: implication for the WHO's elimination strategy. Full Text available with Trip Pro

Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: implication for the WHO's elimination strategy. WHO developed a global strategy to eliminate hepatitis B by 2030 and set target to treat 80% of people with chronic hepatitis B virus (HBV) infection eligible for antiviral treatment. As a first step to achieve this goal, it is essential to conduct a situation analysis that is fundamental to designing national hepatitis plans. We therefore (...) estimated the prevalence of chronic HBV infection, and described the existing infrastructure for HBV diagnosis in Madagascar.We conducted a stratified multi-stage serosurvey of hepatitis B surface antigen (HBsAg) in adults aged ≥18 years using 28 sentinel surveillance sites located throughout the country. We obtained the list of facilities performing HBV testing from the Ministry of Health, and contacted the person responsible at each facility.A total of 1778 adults were recruited from the 28 study

2017 BMC Public Health

74. IFNL4 rs368234815 and rs117648444 variants predict off treatment HBsAg seroclearance in IFN treated HBeAg negative chronic hepatitis B patients. (Abstract)

IFNL4 rs368234815 and rs117648444 variants predict off treatment HBsAg seroclearance in IFN treated HBeAg negative chronic hepatitis B patients. Robust baseline predictors of interferon (IFN) response in HBeAg-negative chronic hepatitis B (CHB) patients are not currently available. The recently described rs368234815 TT/ΔG dinucleotide and rs117648444 nonsynonymous P70S polymorphisms in IFN lambda 4 (IFNL4) gene, which are strongly associated with response to IFN in hepatitis C virus (HCV (...) ) infection, could be also useful in IFN-treated CHB patients. Here we assessed whether IFNL4 rs368234815 and rs117648444 polymorphisms predict IFN-induced HBsAg clearance in CHB patients.We sequenced the IFNL4 gene on genomic DNA collected from 126 HBeAg-negative CHB patients treated with IFN and followed up for a median of 11 (1-23) years.The 15-year cumulative probability of HBsAg loss in the 62 carriers of the rs368234815 TT/TT genotype, which abolishes the IFNλ4 protein production, was comparable

2017 Liver International

75. Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B Full Text available with Trip Pro

virological, biochemical and histological responses and 2) to investigate the patterns of mutations in the reverse transcriptase and surface proteins of HBV with LAM and/or ADF-resistant in partially-responded chronic hepatitis B (CHB) patients.The study group consisted of 186 chronic HBV carriers who were admitted to the Tehran Hepatitis Network from 2010 to 2013. We retrospectively selected 86 patients who partially responded to different nucleoside analogue regimens. After 48 weeks of therapy, five (...) Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B The mutational pattern of chronic Hepatitis B virus (HBV) is unclear in patients who show incomplete response to antiviral therapy. The aims of this study were 1) to determine the benefit of combination therapy with adefovir dipivoxil (ADV) and Lamivudine (LAM) versus ADV or LAM alone in maintaining

2016 Electronic physician

76. Modulation of Tim-3 Expression by Antigen-Dependent and -Independent Factors on T Cells from Patients with Chronic Hepatitis B Virus Infection Full Text available with Trip Pro

in the inductor of Tim-3 expression on T cells, 76 patients with chronic HBV infection (including 40 chronic hepatitis B [CHB] and 36 asymptomatic HBV carriers [AsC]) and 40 of normal controls (NCs) were enrolled in this study. Tim-3 expressions on CD4+ and CD8+ T cells were assessed in response to HBV-encoding antigens, HBV peptide pools, and common γ-chain (γc) cytokines stimulation by flow cytometry. HBV peptides and anti-CD3/CD28 directly induced Tim-3 expression on T cells. γc cytokines also drive Tim-3 (...) Modulation of Tim-3 Expression by Antigen-Dependent and -Independent Factors on T Cells from Patients with Chronic Hepatitis B Virus Infection T-cell immunoglobulin domain and mucin domain-containing molecule-3 (Tim-3) was up-regulated on viral specific T cells and contributed to T cells exhaustion during chronic hepatitis B virus (HBV) infection. However, modulation of Tim-3 expression was still not fully elucidated. To evaluate the potential viral and inflammatory factors involved

2017 Frontiers in cellular and infection microbiology

77. Long-term Nucleos(t)ides Analogues for Chronic Hepatitis B Improve Liver and Spleen Size: A Noninvasive Sonographic Study Full Text available with Trip Pro

Long-term Nucleos(t)ides Analogues for Chronic Hepatitis B Improve Liver and Spleen Size: A Noninvasive Sonographic Study Histological improvement and regression of liver fibrosis after long-term use of nucleos(t)ides analogues (NUCs) have been documented. The aim of the present investigation was to evaluate the usefulness of traditional sonography to detect hepatic and splenic changes during NUC therapy in chronic hepatitis B (CHB) patients.A total of 181 CHB patients receiving NUC treatment (...) were enrolled in this study. The study population was divided into three groups 72 cirrhotic, 58 noncirrhotic CHB, and 51 nonreplicative hepatitis B virus carriers. All patients had blood chemistries taken and sonography at baseline and during the NUC treatment period. The changes in liver size, liver edge, spleen size, platelet count, and platelet count/spleen diameter (PC/SD) ratio were compared among the three groups of patients.CHB Patients with and without cirrhosis have improved clinical

2017 Journal of medical ultrasound

78. Current Condition of Chronic Hepatitis B Virus Infection in Cuban Adults Full Text available with Trip Pro

at least a 6-month history of hepatitis B surface antigen positivity were recruited between 2013 and 2015. Descriptive statistical analysis of the epidemiologic, clinical, biochemical, and virologic variables was performed.Men accounted for 67.8% of patients, and the median age was 43 years. The median time since diagnosis of infection was 9 years. Among the patients, 59% had chronic hepatitis, 34% had liver cirrhosis, and 7% were inactive carriers. Concomitant diagnoses demonstrated that 16.4 (...) Current Condition of Chronic Hepatitis B Virus Infection in Cuban Adults The reduction of the incidence of hepatitis B virus (HBV) infection in Cuba can be attributed to the effectiveness of the national immunization program. However, the number of patients with chronic HBV observed in clinical practice is not negligible.A cross-sectional study was conducted to describe the main clinical characteristics of patients with chronic hepatitis B virus infection.A total of 146 patients who had

2017 Current therapeutic research, clinical and experimental

79. Lower Expression of MicroRNA-155 Contributes to Dysfunction of Natural Killer Cells in Patients with Chronic Hepatitis B Full Text available with Trip Pro

Lower Expression of MicroRNA-155 Contributes to Dysfunction of Natural Killer Cells in Patients with Chronic Hepatitis B MicroRNAs have been reported to be regulated in different ways in a variety of liver diseases. As a key modulator of cellular function in both innate and adaptive immunity, the role of miR-155 in chronic hepatitis B virus infection remains largely unknown. Here, we investigated the expression and function of miR-155 in chronic hepatitis B (CHB) patients. It was found that miR (...) -155 expression in peripheral blood mononuclear cells (PBMCs) was lower in CHB patients than healthy controls (HC). Among CHB infection, immune-active (IA) patients with abnormal alanine aminotransferase (ALT) levels had relatively higher miR-155 expression in PBMCs and serum than immune-tolerant carriers, but were comparable to inactive carriers. Moreover, there was a positive correlation between miR-155 expression and ALT levels in CHB patients. Particularly, miR-155 expression in natural killer

2017 Frontiers in immunology

80. Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease Full Text available with Trip Pro

Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease Chronic hepatitis B has highly a dynamic course with significant fluctuations of HBV-DNA and ALT impeding assessment of disease activity. New biomarkers of inflammatory versus noninflammatory stages of HBV infection are urgently needed. Cytokeratin 18 epitope M30 (M30 CK-18) is a sensitive marker of cell death. We aimed to investigate an association between serum M30 CK-18 (...) and histological activity and phase of HBV infection. 150 Caucasian patients with HBV-infection were included in the study. Serum M30 CK-18 levels reflected phase of disease, being significantly higher in both HBeAg(+) and HBeAg(-) hepatitis B in comparison to HBsAg(+) carrier groups. The highest serum M30 CK-18 levels were observed in subjects with the most advanced stages of HBV. Moreover, its serum concentrations correlated with both inflammatory activity and fibrosis advancement (ANOVA P < 0.001

2017 Mediators of inflammation

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>